Glenmark drug for treating uncontrolled asthma gets Indian regulator's nod

Company says treatment will be affordable and improve lung function of patients

Mumbai-based Glenmark has got the Indian regulator’s approval for a drug to treat patients of uncontrolled asthma. The fixed dose combination (FDC) drug will be sold under the brand name Indamet.

An FDC drug combines two or more active ingredients into a single pill in a fixed dosage ratio. Indamet--a combination of Indacaterol and Mometasone--will be available in three strengths and it will be priced between Rs 349 and Rs 449.

"We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents